MULTI-CANCER
EARLY DETECTION(MCED)
Emerging multi-cancer early detection tests have the potential to identify molecular signals associated with multiple cancers, including cancer types for which routine screening is not currently available.
Early cancer detection may reduce late-stage diagnoses, expand treatment options, improve survival, and ultimately lead to better patient outcomes. However, current routine screening is limited to only a small number of cancer types.
AI-driven, data-based insights are at the core of our approach to identifying MCED biomarkers. By integrating artificial intelligence with advanced data analytics, we aim to translate complex biological and clinical data into clear, actionable insights that may support earlier diagnosis, improve patient outcomes, and advance public health.
MCED tests could transform cancer screening by enabling the simultaneous detection of multiple cancer types through a single test.
